Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.71 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.64 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828025 | 0.91 | CRBN (0.65) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL19503550 | 0.87 | IKZF2 (0.74) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL29547357 | 0.87 | IKZF2 (0.74) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL25571538 | 0.87 | IKZF2 (0.74) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL23226142 | 0.86 | CRBN (0.70) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL31546799 | 0.85 | CRBN (0.72) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL23729630 | 0.85 | CRBN (0.72) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL24654417 | 0.85 | CRBN (0.88) | CRBNIKZF2CSNK1A1GSPT1DDB1 | |
| SCHEMBL19503565 | 0.84 | IKZF2 (0.73) | CRBNIKZF2CSNK1A1DDB1 | |
| SCHEMBL34466492 | 0.84 | CRBN (0.69) | CRBNIKZF2CSNK1A1GSPT1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | CRBN 330/4885IKZF2 2170/4885CSNK1A1 62/4885 |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | CRBN 286/4885IKZF2 2378/4885CSNK1A1 3214/4885 |
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | CRBN 3528/4885IKZF2 3455/4885CSNK1A1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.